AUTHOR=Li Yongbiao , Cui Ruyi , Liu Shaobo , Qin Zhiping , Sun Wenjing , Cheng Yong , Liu Qingshan 

TITLE=The efficacy and safety of post-stroke cognitive impairment therapies: an umbrella review

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1207075

DOI=10.3389/fphar.2023.1207075

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Stroke survivors are at significantly increased risk of cognitive impairment, which affects patients’ independence of activities of daily living (ADLs), social engagement, and neurological function deficit. Many studies have been done to evaluate the efficacy and safety of post-stroke cognitive impairment (PSCI) treatment, and due to the largely inconsistent clinical data, there is a need to summarize and analyze the published clinical research data in this area.</p><p><bold>Objective:</bold> An umbrella review was performed to evaluate the efficacy and safety of PSCI therapies.</p><p><bold>Methods:</bold> Three independent authors searched for meta-analyses and systematic reviews on PubMed, the Cochrane Library, and the Web of Science to address this issue. We examined ADL and Barthel index (BI), Montreal Cognitive Assessment (MoCA), neurological function deficit as efficacy endpoints, and the incidence of adverse events as safety profiles.</p><p><bold>Results:</bold> In all, 312 studies from 19 eligible publications were included in the umbrella review. The results showed that angiotensin-converting enzyme inhibitors (ACEI) and N-methyl-D-aspartate (NMDA) antagonists, cell therapies, acupuncture, and EGB76 can improve the MoCA and ADL, and the adverse effects were mild for the treatment of PSCI. Moreover, Vinpocetine, Oxiracetam, Citicoline, thrombolytic therapy, Actovegin, DL-3-n-Butylphthalide, and Nimodipine showed adverse events or low article quality in patients with PSCI. However, the research evidence is not exact and further research is needed.</p><p><bold>Conclusion:</bold> Our study demonstrated that ACEI inhibitors (Donepezil) and NMDA antagonists (Memantine), EGB761, and acupuncture are the ADL and BI, MoCA, and neurological function deficit medication/therapy, respectively, for patients with PSCI.</p><p><bold>Clinical Trial Registration:</bold><ext-link ext-link-type="uri" xlink:href="https://inplasy.com/inplasy-2022-11-0139/" xmlns:xlink="http://www.w3.org/1999/xlink">https://inplasy.com/inplasy-2022-11-0139/</ext-link>; Identifier: INPLASY2022110139.</p>